Evaluation of melatonin effect on breast cancer

The effect of melatonin supplementation on tumor grading, pathologic findings, serum levels of biomarkers related to inflammation and oxidative stress in patient with breast cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171105037262N5

Enrollment

Registered

2020-10-18

Start date

2020-01-21

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention group: Receiving chemotherapy and melatonin supplementation. Every night one hour prior to sleep, patients will orally receive two 5mg capsules of melatonin for 24 weeks.

Eligibility

Sex/Gender

Female

Age

25 Years to No maximum

Inclusion criteria

Inclusion criteria: Having breast cancer at any stage undergoing neoadjuvant chemotherapy Above 25 years of age

Exclusion criteria

Exclusion criteria: Having renal and liver failure Abnormal blood test

Design outcomes

Primary

Measure	Time frame
Tumor grade. Timepoint: At the beginning and end of intervention. Method of measurement: Microscopic.	—

Secondary

Measure	Time frame
Serum levels of biomarkers related to inflammation and oxidative stress. Timepoint: At the beginning and end of interventio. Method of measurement: ELISA.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026